These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 38203494)

  • 1. Enhancing Immunotherapy in Ovarian Cancer: The Emerging Role of Metformin and Statins.
    Almeida-Nunes DL; Silvestre R; Dinis-Oliveira RJ; Ricardo S
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis.
    Majidi A; Na R; Dixon-Suen S; Jordan SJ; Webb PM
    Gynecol Oncol; 2020 Jun; 157(3):678-685. PubMed ID: 32317171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials.
    Sun J; Yuan Y; Cai R; Sun H; Zhou Y; Wang P; Huang R; Xia W; Wang S
    BMJ Open; 2015 Mar; 5(3):e007280. PubMed ID: 25818277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study.
    Urpilainen E; Marttila M; Hautakoski A; Arffman M; Sund R; Ilanne-Parikka P; Arima R; Kangaskokko J; Puistola U; Hinkula M; Läärä E
    BMC Cancer; 2018 Jul; 18(1):767. PubMed ID: 30055585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.
    Nunes M; Henriques Abreu M; Bartosch C; Ricardo S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of "Repurposed" Drugs in the Treatment of Epithelial Ovarian Cancer: A Systematic Review.
    Goenka L; Dubashi B; Selvarajan S; Ganesan P
    Am J Clin Oncol; 2022 Apr; 45(4):168-174. PubMed ID: 35320817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells.
    Xuan Y; Wang H; Yung MM; Chen F; Chan WS; Chan YS; Tsui SK; Ngan HY; Chan KK; Chan DW
    Theranostics; 2022; 12(7):3534-3552. PubMed ID: 35547771
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer.
    Göbel A; Zinna VM; Dell'Endice S; Jaschke N; Kuhlmann JD; Wimberger P; Rachner TD
    BMC Cancer; 2020 Jul; 20(1):703. PubMed ID: 32727400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients.
    Ghazeeri G; Abbas HA; Skaff B; Harajly S; Awwad J
    J Endocrinol Invest; 2015 Jun; 38(6):643-51. PubMed ID: 25722221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Tumor Microenvironment in Ovarian Cancer Ascites.
    Almeida-Nunes DL; Mendes-Frias A; Silvestre R; Dinis-Oliveira RJ; Ricardo S
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer.
    Greenaway JB; Virtanen C; Osz K; Revay T; Hardy D; Shepherd T; DiMattia G; Petrik J
    Oncotarget; 2016 Jul; 7(30):47343-47365. PubMed ID: 27329838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.
    Kobayashi Y; Banno K; Kunitomi H; Tominaga E; Aoki D
    J Gynecol Oncol; 2019 Jan; 30(1):e10. PubMed ID: 30479094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients.
    Yang Q; Bae G; Nadiradze G; Castagna A; Berezhnoy G; Zizmare L; Kulkarni A; Singh Y; Weinreich FJ; Kommoss S; Reymond MA; Trautwein C
    J Transl Med; 2022 Dec; 20(1):581. PubMed ID: 36503580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response.
    Yang H; Gu X; Fan R; Zhu Q; Zhong S; Wan X; Chen Q; Zhu L; Feng F
    J Ovarian Res; 2023 Nov; 16(1):223. PubMed ID: 37993916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case-control study.
    Urpilainen E; Marttila M; Hautakoski A; Arffman M; Sund R; Ilanne-Parikka P; Arima R; Kangaskokko J; Puistola U; Läärä E; Hinkula M
    BJOG; 2018 Jul; 125(8):1001-1008. PubMed ID: 29412502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copper content in ascitic fluid is associated with angiogenesis and progression in ovarian cancer.
    Onuma T; Mizutani T; Fujita Y; Yamada S; Yoshida Y
    J Trace Elem Med Biol; 2021 Dec; 68():126865. PubMed ID: 34601284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ascites N-glycome of epithelial ovarian cancer patients.
    Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
    J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible Role of Metformin as an Immune Modulator in the Tumor Microenvironment of Ovarian Cancer.
    Tsogas FK; Majerczyk D; Hart PC
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-Cell Sequencing of Malignant Ascites Reveals Transcriptomic Remodeling of the Tumor Microenvironment during the Progression of Epithelial Ovarian Cancer.
    Li Y; Wang W; Wang D; Zhang L; Wang X; He J; Cao L; Li K; Xie H
    Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational modeling of malignant ascites reveals CCL5-SDC4 interaction in the immune microenvironment of ovarian cancer.
    Kim S; Han Y; Kim SI; Lee J; Jo H; Wang W; Cho U; Park WY; Rando TA; Dhanasekaran DN; Song YS
    Mol Carcinog; 2021 May; 60(5):297-312. PubMed ID: 33721368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.